{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:29:04Z","timestamp":1767961744443,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":3633,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.jpainsymman.2009.07.010","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T10:13:08Z","timestamp":1265710388000},"page":"296-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Systematic Review of Oxymorphone in the Management of Chronic Pain"],"prefix":"10.1016","volume":"39","author":[{"given":"Fadia","family":"Mayyas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2009.07.010_bib1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1090-3801(02)00143-X","article-title":"Recommendations for using opioids in chronic non-cancer pain","volume":"7","author":"Kalso","year":"2003","journal-title":"Eur J Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/sj.bjc.6603162","article-title":"Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review","volume":"94","author":"Bell","year":"2006","journal-title":"Br J\u00a0Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0885-3924(02)00383-4","article-title":"Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial","volume":"23","author":"Caldwell","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0304-3959(02)00020-9","article-title":"Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain\u2014results of a double-blind placebo-controlled trial (MONTAS)","volume":"97","author":"Maier","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archinte.160.6.853","article-title":"Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation","volume":"160","author":"Roth","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","article-title":"Morphine and alternative opioids in cancer pain: the EAPC recommendations","volume":"84","author":"Hanks","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0","article-title":"Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration","volume":"76","author":"Cherny","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(92)90192-E","article-title":"Individual variability in the response to different opioids: report of five cases","volume":"49","author":"Galer","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib10","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P","article-title":"Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics","volume":"72","author":"Crews","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0952-8180(89)90022-6","article-title":"A comparison of oxymorphone and fentanyl as narcotic supplements in general anesthesia","volume":"1","author":"Sinatra","year":"1989","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2001.112689","article-title":"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide","volume":"69","author":"Madsen","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/archinte.1995.00430180043006","article-title":"Drug-related morbidity and mortality. A cost-of-illness model","volume":"155","author":"Johnson","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","article-title":"Clinical pharmacology of opioids for pain","volume":"18","author":"Inturrisi","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1592\/phco.24.5.468.33347","article-title":"Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study","volume":"24","author":"Adams","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5055\/jom.2008.0018","article-title":"Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review","volume":"4","author":"Sloan","year":"2008","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/TCRM.S1784","article-title":"Review of oral oxymorphone in the management of pain","volume":"4","author":"Sloan","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib19","first-page":"109","article-title":"Oxymorphone: a review","volume":"14","author":"Prommer","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1345\/aph.1H451","article-title":"Oral oxymorphone for pain management","volume":"41","author":"Chamberlin","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-3565(25)12962-5","article-title":"The analgesic equivalence to morphine and relative side action liability of oxymorphone (14-hydroxydihydro morphinone)","volume":"125","author":"Eddy","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib22","first-page":"209","article-title":"Oxymorphone revisited","volume":"7","author":"Sinatra","year":"1988","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00126839-200506020-00004","article-title":"Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets","volume":"6","author":"Adams","year":"2005","journal-title":"Drugs R D"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1213\/01.ANE.0000132548.91622.B3","article-title":"The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain","volume":"99","author":"Gimbel","year":"2004","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0090-9556(25)08048-1","article-title":"Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog","volume":"11","author":"Cone","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0091270004271969","article-title":"Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways","volume":"45","author":"Adams","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000542-198502000-00005","article-title":"Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone","volume":"62","author":"Hermens","year":"1985","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib28","first-page":"57","article-title":"Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study","volume":"13","author":"Sloan","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/030079904125003854","article-title":"Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study","volume":"20","author":"Gabrail","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1526-4637.2005.00057.x","article-title":"Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial","volume":"6","author":"Matsumoto","year":"2005","journal-title":"Pain Med"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpain.2004.09.005","article-title":"Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study","volume":"6","author":"Hale","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.clinthera.2006.03.008","article-title":"A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee","volume":"28","author":"Kivitz","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpain.2006.09.011","article-title":"Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study","volume":"8","author":"Hale","year":"2007","journal-title":"J Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1185\/030079906X162692","article-title":"A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain","volume":"23","author":"Katz","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.mjt.0000139442.65914.f9","article-title":"Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study","volume":"12","author":"McIlwain","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/009127007701700402","article-title":"Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer","volume":"17","author":"Beaver","year":"1977","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib37","series-title":"Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. CRD report no. 4","author":"Centre for Reviews and Dissemination (CRD)","year":"2001"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1399-6576.2006.01089.x","article-title":"Transfusion vs. alternative treatment modalities in acute bleeding: a systematic review","volume":"50","author":"Heier","year":"2006","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence based guidelines","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib40","series-title":"Review Manager (Rev Man), version 5.0","year":"2008"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib41","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.8.10.1515","article-title":"Oral extended-release oxymorphone: a new choice for chronic pain relief","volume":"8","author":"Matsumoto","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0895-4356(94)00097-A","article-title":"Best evidence synthesis: an intelligent alternative to meta-analysis","volume":"48","author":"Slavin","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/1467-8519.00332","article-title":"Update on unethical use of placebos in randomised trials","volume":"17","author":"Michels","year":"2003","journal-title":"Bioethics"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJM199408113310611","article-title":"The continuing unethical use of placebo controls","volume":"331","author":"Rothman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib46","first-page":"344","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstrom","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpainsymman.2009.07.010_bib47","series-title":"OPANA ER\u00ae (oxymorphone hydrochloride). Full prescribing information","year":"2006"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392409011403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392409011403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:54Z","timestamp":1760130234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392409011403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0885392409011403"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.07.010","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Oxymorphone in the Management of Chronic Pain","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}